Increased Risk of Keratinocyte Carcinomas, Merkel Cell Carcinoma, and Other Skin Cancers in Patients Treated With Janus Kinase 1 and 2 Inhibitor, Ruxolitinib.
Nadine Elias DababnehMahan MaaziSaid DababnehGizelle PopradiIvan V LitvinovPublished in: Journal of cutaneous medicine and surgery (2024)